Dihexa in Clinical Trials: What We've Learned So Far The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP 1 or glucagon receptors Nature Communications Dihexa: A Comprehensive Guide to This Promising Peptide